Rapid Neuromodulation and Mast Cell Targeting in Chronic Pruritus
Chronic pruritus is increasingly understood as a neuro-immune disorder rather than a purely inflammatory skin condition. At the 2026 Masterclasses in Dermatology Annual Meeting, Gil Yosipovitch, MD, emphasized that effective itch management requires directly targeting neuronal signaling pathways and mast cell activation, particularly in itch-dominant diseases such as prurigo nodularis (PN). Emerging biologics and small molecules are reshaping treatment algorithms by prioritizing rapid symptom control and mechanistic precision.
A central focus of the discussion was nemolizumab, a humanized monoclonal antibody targeting the IL-31 receptor alpha subunit. IL-31 is a key driver of Th2-mediated pruritus and directly activates peripheral sensory neurons, functioning as a final common itch pathway. By blocking IL-31RA, nemolizumab interrupts neurosensory transmission rather than solely suppressing downstream inflammation. This distinction is clinically meaningful in PN, where itch severity often exceeds visible inflammatory burden.
Phase 3 data in PN demonstrated a rapid and robust anti-pruritic response. Itch reduction was observed as early as day 2, with clinically significant improvement by week 4. At week 4, 41% of patients receiving nemolizumab achieved a ≥4-point improvement in Peak Pruritus Numeric Rating Scale (PP-NRS) compared with 7.7% of patients receiving placebo. The median time to meaningful NRS response was approximately 19 days. Dr Yosipovitch highlighted that early itch suppression is particularly impactful for patients with severe sleep disruption and impaired quality of life. Importantly, long-term extension data extending to 100 weeks demonstrate sustained efficacy and durability, supporting nemolizumab as a viable long-term strategy for PN management.
Beyond PN, emerging and real-world data suggest broader applicability. Nemolizumab has demonstrated benefit in chronic kidney disease–associated pruritus, including patients with advanced renal disease, as well as in chronic pruritus of unknown origin and certain neuropathic itch phenotypes. Given its rapid onset, strong anti-pruritic effect, and neuronally targeted mechanism, nemolizumab may now represent a preferred option in itch-dominant PN, particularly when rapid symptom control is a priority.
The session also underscored mast cells as critical amplifiers of chronic itch. Described as biologic “bombs,” mast cells release a diverse array of pruritogenic mediators, including histamine, cytokines, proteases, and neuroactive substances. Targeting mast cell activation through inhibition of upstream signaling pathways represents a rational and evolving therapeutic strategy.
Remibrutinib, a highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, exemplifies this approach. By inhibiting BTK-mediated mast cell activation, remibrutinib produces rapid itch relief, with reductions reported within hours and significant improvement by day 1 in mast cell–driven disease. Its short clinical endpoints and rapid onset may position it as a transformative therapy for severe or refractory itch conditions. Additional mast cell–directed therapies are also emerging. Barzolvolimab, which targets KIT signaling and reduces mast cell activity, has demonstrated significant anti-pruritic effects in PN, further validating mast cells as therapeutic targets.
Neuromodulatory strategies also remain relevant in refractory pruritus. Butorphanol nasal spray, a kappa-opioid receptor agonist and mu-opioid receptor antagonist, has been used off label with reported benefit in intractable itch conditions, including PN, cholestatic itch, and lymphoma-associated pruritus, particularly when nocturnal symptoms predominate.
In practical prescribing pearls, Dr Yosipovitch emphasized matching mechanism to phenotype. Dupilumab may be favored in type 2–driven inflammatory disease or when multi-disease control is desired; lebrikizumab may appeal to patients prioritizing monthly dosing; nemolizumab is particularly suited for itch-dominant disease such as PN; JAK inhibitors may be useful for rapid short-term control during flares; remibrutinib may be preferred in mast cell–driven conditions such as chronic spontaneous urticaria; topical JAK inhibitors can address localized inflammatory itch; GABAergic agents may be considered for neuropathic itch; and agents such as mirtazapine or butorphanol may assist in managing nocturnal pruritus.
As the therapeutic landscape expands, chronic itch management is shifting toward rapid neuromodulation, mast cell stabilization, and precision immunologic targeting. These advances signal a move from broadly suppressing inflammation to strategically interrupting the biologic circuitry of itch itself.
Reference:
Yosipovitch G. Itch happens: new insights, new treatments. Presented at: Masterclasses in Dermatology; February 19–22, 2026; Sarasota, FL.
